DOUBLE BLIND STUDY OF GCSF ADMINISTRATION TO NEONATES WITH NEUTROPENIA

GCSF 对中性粒细胞减少症新生儿给药的双盲研究

• 批准号: 6114839
• 负责人: KURT R SCHIBLER
• 金额: $ 2.81万
• 依托单位: UNIVERSITY OF UTAH
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6114839
• 关键词: blood disorder chemotherapy; blood toxicology; clinical research; colitis; colony stimulating factor; drug screening /evaluation; granulocytopenia; human subject; human therapy evaluation; immunotherapy; neutrophil; newborn human (0-6 weeks); pediatric pharmacology; placebos; pregnancy toxemia /hypertension; blood disorder chemotherapy; blood toxicology; clinical research; colitis; colony stimulating factor; drug screening /evaluation; granulocytopenia; human subject; human therapy evaluation; immunotherapy; neutrophil; newborn human (0-6 weeks); pediatric pharmacology; placebos; pregnancy toxemia /hypertension

The study will determine if G-CSF administration to newborn infants with neurtropenia associated with possible congenital or acquired sepsis, maternal pregnancy-induced hypertension, or necrotizing entercolitis results in rapid resolution of neutropenia, improved neutrophil function, less frequent and less severe illness, and improved survival compared to placebo-treated control infants.

这项研究将确定G-CSF是否对具有 与可能的先天性或败血症相关的神经元减少症， 孕产妇诱发的高血压或坏死性肠炎 导致中性粒细胞减少症的快速分辨率，改善中性粒细胞 功能，频率较小，疾病较少，生存率提高 与安慰剂治疗的对照婴儿相比。